Roche's Trontinemab Enters Landmark Trial to Prevent Alzheimer's Before Symptoms Emerge
Key Insights
Roche's next-generation anti-amyloid (search) antibody trontinemab is entering a global trial of approximately 1,600 people aged 55 and over at high risk of Alzheimer's but without cognitive symptoms.
Trontinemab uses a "shuttle" molecule to cross the blood-brain barrier more efficiently, with earlier data showing amyloid (search) clearance in 9 out of 10 patients after 28 weeks.
The trial represents a shift from treating symptomatic patients to potentially preventing disease onset, with blood tests for p-tau217 (search) used to identify eligible participants.
A new Alzheimer's disease (search) trial described by leading researchers as a potential "game changer" is now underway, testing whether Roche's next-generation anti-amyloid (search) antibody trontinemab can stop the disease before symptoms ever appear. The global study will enroll approximately 1,600 people across 18 countries, targeting individuals aged 55 and over who are at high risk of Alzheimer's but have not yet developed cognitive impairment.
The trial marks a pivotal shift in Alzheimer's research strategy. Rather than treating patients who already show signs of cognitive decline, investigators will use blood tests to identify those with elevated levels of p-tau217 (search), a biomarker strongly linked to Alzheimer's pathology, and intervene before symptoms manifest.
A Next-Generation Approach to Amyloid (search) Clearance
Trontinemab, manufactured by Swiss pharmaceutical firm Roche, represents an evolution beyond the first wave of anti-amyloid (search) therapies. The drug combines gantenerumab, a previously tested antibody, with a "shuttle" molecule that binds to transferrin receptors, effectively tricking the brain into taking up more of the therapeutic antibody across the blood-brain barrier.
Professor Rob Howard, an expert in old age psychiatry at University College London, explained the mechanism: "The anti-amyloid (search) antibodies that have been used in the past, probably about 1% of what's infused into the patient actually gets into the brain. By linking one of the antibody molecules to a molecule of transferrin, you sort of trick the brain into taking it up and get more of the antibody into the brain, more quickly."
This enhanced delivery appears to translate into faster amyloid (search) clearance. Data from a smaller study involving 178 patients and 477 brain scans indicated that trontinemab cleared amyloid in nine out of 10 patients after 28 weeks. Those on the highest dose may achieve amyloid clearance in as little as three months.
The dosing regimen involves seven monthly infusions, followed by maintenance doses administered every three months.
Building on Earlier Successes
Trontinemab follows lecanemab and donanemab, the first anti-amyloid (search) drugs proven to tackle the underlying cause of Alzheimer's. Those treatments demonstrated the ability to slow cognitive decline by 27% and 35%, respectively. However, both were rejected for NHS use in the UK after regulators judged their benefits too small to justify the cost. Additionally, both earlier drugs were associated with brain bleeding in approximately one in four patients.
Early evidence suggests trontinemab may cause fewer incidents of brain swelling and bleeding than its predecessors. If confirmed in larger trials, this improved safety profile could reduce monitoring requirements and potentially lower treatment costs.
Cautious Optimism Among Experts
While enthusiasm for the trial is considerable, leading voices in the field urge measured expectations. Professor Howard cautioned: "What we don't know yet is whether it has more of an effect on the actual Alzheimer's disease (search) process and the symptoms. No one has ever shown that you can actually reduce the number of people who move from having amyloid (search) in their brains to having dementia with this treatment."
He added: "It could be a game-changer and breakthrough, but we haven't got any real data yet."
Dr Rachel Buckley, associate professor of neurology at Harvard Medical School, struck a more optimistic tone, stating: "If these trials are positive, the game changes."
Hilary Evans-Newton, chief executive of Alzheimer's Research UK, framed the trial within a broader transformation in the field: "The first wave of anti-amyloid (search) drugs has already shown that it is possible to change the course of Alzheimer's, moving from managing symptoms to targeting the underlying disease. Now, the next generation of potential treatments is asking an even bigger question: can we intervene earlier, more effectively and, we hope, more safely, before memory and thinking are badly affected?"
She predicted that over the next five to ten years, the field will see "a transformation in what's possible, including the prospect of treatments that help protect brain health before symptoms progress — the concept of a 'statin for the brain.'"
Dr Emer MacSweeney, consultant neuroradiologist and CEO at Re:Cognition Health, which is participating in the trontinemab trial, described the study as "another hugely encouraging step forward in Alzheimer's research" that "reflects the remarkable momentum we are now seeing in the development of disease-modifying treatments."
Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, called the trontinemab trials "among the most anticipated and exciting developments we have seen in Alzheimer's research for some time."
Dr Jacqui Hanley, head of research funding at Alzheimer's Research UK, emphasized the strategic significance: the trial represents "an important shift" from focusing on "people who already have symptoms towards finding those most at risk and seeing whether treatment can delay, or perhaps one day prevent symptoms developing."